Millions of Americans take statin medications to lower their low-density lipoprotein cholesterol (LDL-C) and reduce their risk of heart attack and stroke. These medications are among the most widely prescribed drugs in cardiovascular medicine. Yet one of the most important questions patients should ask before starting a statin is rarely the focus of conversations about treatment:
How much will this medication actually reduce my personal risk of having a heart attack or stroke?
The answer requires understanding two different ways researchers report treatment benefits: relative risk reduction and absolute risk reduction.
Although both are mathematically legitimate, they communicate different information. Relative risk reductions can sound impressive, particularly when presented without the corresponding absolute numbers. A medication advertised as reducing heart attack risk by 36%, for example, may reduce the actual probability of an event by only about one percentage point in the population studied.
This distinction matters because patients should understand not only whether a medication works, but also how much benefit they can reasonably expect based on their individual cardiovascular risk.
Research has demonstrated that statins reduce cardiovascular events in appropriately selected populations. However, the magnitude of the benefit varies considerably depending on a person’s baseline risk, existing cardiovascular disease, age, and other clinical characteristics (Cholesterol Treatment Trialists’ [CTT] Collaboration, 2012).
Understanding these differences is essential to informed medical decision-making.
Understanding Absolute Risk
Absolute risk refers to the actual probability that a particular event will occur within a defined period.
Consider a hypothetical clinical trial involving 200 people followed for five years.
Among 100 individuals who do not take a statin, two experience a heart attack. Their absolute risk is 2%.
Among 100 individuals who take a statin, one experiences a heart attack. Their absolute risk is 1%.
The absolute risk reduction is calculated by subtracting the risk in the treatment group from the risk in the comparison group.
Absolute risk reduction = 2% − 1% = 1 percentage point.
In practical terms, one fewer person out of every 100 experienced a heart attack over five years.
The medication provided a measurable benefit, but 98 of the 100 untreated individuals also did not experience a heart attack during that period.
This does not establish that the medication was unnecessary. Rather, it illustrates why the size of the benefit matters when considering treatment.
Absolute risk is especially useful because it communicates the expected benefit in terms that patients can more easily understand.
Understanding Relative Risk
Relative risk reduction expresses how much the risk decreases proportionally compared with the original risk.
Using the same hypothetical example, the untreated group’s heart attack risk was 2%, while the statin group’s risk was 1%.
The relative risk reduction is:
Relative risk reduction = (2% − 1%) ÷ 2% × 100 = 50%.
Therefore, a researcher could accurately report that the statin reduced heart attack risk by 50%.
However, the absolute risk reduction was only one percentage point over five years.
Both statements are mathematically correct:
- The medication reduced relative risk by 50%.
- The medication reduced absolute risk by one percentage point.
The concern arises when the 50% relative risk reduction is communicated without explaining that the actual risk declined from 2% to 1%.
Research on risk communication has shown that relative risk presentations can make treatment effects appear larger to patients and clinicians than presentations using absolute risk differences (Covey, 2007).
For this reason, patients should request both measurements before making treatment decisions.
The Lipitor 36% Claim: What the Numbers Actually Show
One of the most recognizable examples of relative risk marketing involved Lipitor (atorvastatin), a cholesterol-lowering medication manufactured by Pfizer.
Advertisements promoted the claim that Lipitor reduced the risk of heart attack by 36%.
That figure originated from the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA), which evaluated atorvastatin among adults with hypertension and additional cardiovascular risk factors who did not have a prior history of coronary heart disease (Sever et al., 2003).
The trial included 10,305 participants and was stopped early after a median follow-up of approximately 3.3 years because of a significant reduction in the primary coronary endpoint.
The results were revealing.
Approximately 3.0% of participants receiving placebo experienced a nonfatal heart attack or fatal coronary heart disease event, compared with approximately 1.9% of those receiving atorvastatin.
This represented an absolute risk reduction of approximately 1.1 percentage points over 3.3 years.
Expressed differently, approximately 11 fewer coronary events occurred for every 1,000 people treated during that period.
Yet when the same result was expressed as a proportional reduction, the reported benefit was approximately 36%.
The 36% relative risk reduction and the approximately 1.1-percentage-point absolute risk reduction describe the same clinical trial result.
The difference is how the information is presented.
A patient hearing only that Lipitor reduces heart attack risk by 36% could reasonably interpret that claim as meaning 36 out of every 100 people would avoid a heart attack because they took the medication.
That interpretation would be incorrect.
The actual trial results showed a much smaller difference in the proportion of people experiencing the primary coronary endpoint.
Importantly, ASCOT-LLA followed participants for approximately 3.3 years, not five years. This distinction is essential when accurately communicating the evidence.
The study also involved a specific population of adults with hypertension and additional risk factors. Its results should not automatically be applied to every person with elevated LDL cholesterol.
Number Needed to Treat: Another Important Measurement
A third measurement can make treatment benefits easier to understand: the number needed to treat (NNT).
NNT estimates how many individuals must receive a treatment over a specified period to prevent one additional adverse event.
It is calculated as:
NNT = 1 ÷ Absolute risk reduction (expressed as a decimal).
Using the approximately 1.1% absolute risk reduction from ASCOT-LLA:
NNT = 1 ÷ 0.011 ≈ 91.
This means approximately 91 people would need to receive atorvastatin for about 3.3 years to prevent one additional event included in the trial’s primary coronary endpoint.
The other approximately 90 people would not experience that particular additional preventive benefit during the observation period. Some might nevertheless benefit through other cardiovascular outcomes, and the calculation does not identify in advance which individual will benefit.
NNT is not a universal number for statins.
People with established cardiovascular disease or substantially elevated baseline risk may experience larger absolute benefits, resulting in a lower NNT. Conversely, individuals with very low baseline cardiovascular risk may have a smaller absolute benefit.
This is why a personalized assessment is more informative than relying on a single advertising statistic.
What Does the Broader Scientific Evidence Show?
It would be inaccurate to conclude from the Lipitor example that statins do not work.
Large randomized clinical trials and meta-analyses have demonstrated that statins reduce major cardiovascular events.
The CTT Collaboration (2012) analyzed individual participant data from 27 randomized trials involving approximately 175,000 participants.
The researchers reported that lowering LDL cholesterol by approximately 1 mmol/L (38.7 mg/dL) was associated with a reduction of roughly one-fifth in major vascular events, including among people at relatively low cardiovascular risk.
However, the absolute benefit depended on the individual’s starting risk.
For example, the analysis estimated that among people with a five-year major vascular event risk below 10%, reducing LDL cholesterol by 1 mmol/L would prevent approximately 11 major vascular events per 1,000 people treated over five years.
That corresponds to an absolute reduction of approximately 1.1 percentage points in that risk category.
These findings demonstrate an important principle: a treatment can produce a meaningful proportional reduction in risk while offering a relatively modest absolute benefit to an individual whose starting risk is low.
In higher-risk patients, particularly those with established cardiovascular disease, the absolute benefit can be considerably greater.
Therefore, the most scientifically appropriate question is not simply whether statins lower LDL cholesterol.
It is whether the expected reduction in cardiovascular events is sufficiently meaningful for a particular patient to justify the medication’s potential risks, costs, and treatment burden.
What About Statin Side Effects?
Understanding treatment benefits is only one part of informed consent.
Patients should also understand potential adverse effects.
Statin-associated muscle symptoms are frequently reported in clinical practice, although randomized trials indicate that many muscle complaints occurring during treatment are not caused by the medication itself.
A large individual-participant-data meta-analysis found a small excess of muscle pain or weakness associated with statin therapy, particularly during the first year of treatment (CTT Collaboration, 2022).
Statins are also associated with a modest increase in the risk of developing diabetes, particularly among individuals already predisposed to elevated blood glucose (Sattar et al., 2010).
Serious muscle injury, including rhabdomyolysis, is rare. Clinically significant liver injury is also uncommon.
These risks should be considered in the context of the individual’s expected cardiovascular benefit.
For a patient who has already experienced a heart attack, the potential benefit of statin therapy may substantially outweigh the risk of adverse effects.
For someone with low estimated cardiovascular risk, the decision may be less straightforward.
Patients deserve a balanced discussion rather than an assumption that every person with elevated LDL cholesterol requires identical treatment.
Cholesterol Is Only One Part of Cardiovascular Risk
An additional limitation of cholesterol-centered discussions is that LDL-C represents only one component of cardiovascular risk.
Atherosclerotic cardiovascular disease develops through a complex interaction of circulating atherogenic lipoproteins, arterial wall biology, inflammation, blood pressure, metabolic health, genetic predisposition, and other factors.
Important measurements that may help refine risk assessment include apolipoprotein B (ApoB), lipoprotein(a) [Lp(a)], and coronary artery calcium (CAC).
ApoB provides an estimate of the number of circulating atherogenic lipoprotein particles. Lp(a) is a genetically influenced cardiovascular risk factor that may remain elevated even when conventional cholesterol results appear relatively favorable.
CAC scoring uses computed tomography to identify calcified plaque in the coronary arteries and can be particularly useful when the decision to initiate preventive medication remains uncertain (Grundy et al., 2019).
These measurements do not replace a comprehensive clinical assessment, but they can provide important information beyond LDL-C alone.
Lifestyle interventions also remain essential.
Improving dietary quality, increasing physical activity, addressing insulin resistance, controlling blood pressure, avoiding tobacco exposure, maintaining healthy body composition, and improving metabolic health can reduce cardiovascular risk through multiple pathways.
Importantly, lifestyle interventions and statin therapy are not necessarily competing approaches. In higher-risk individuals, both may be appropriate.
Why Patients Should Ask Better Questions
Before agreeing to long-term statin therapy, patients should be encouraged to ask their healthcare professional several questions:
-
- What is my estimated absolute risk of heart attack or stroke over the next five or ten years?
- How much would a statin reduce that risk in absolute percentage points?
- What is the relative risk reduction, and how does it compare with the absolute reduction?
- What is the estimated number needed to treat for someone with my risk profile?
- What are the potential side effects, and how frequently do they occur?
- Would ApoB, Lp(a), or CAC testing help clarify my cardiovascular risk?
- What lifestyle interventions could meaningfully improve my risk profile?
- How would my treatment recommendation change if my overall cardiovascular risk were substantially lower or higher?
These questions are not intended to discourage appropriate medical treatment.
They are intended to promote transparency, informed consent, and individualized care.
Conclusion: Patients Deserve the Complete Numbers
The historical Lipitor advertising claim illustrates why the distinction between relative and absolute risk matters.
A reported 36% relative reduction in coronary events sounds substantial. Yet in the ASCOT-LLA population, the corresponding absolute reduction was approximately 1.1 percentage points over 3.3 years.
Neither figure is inherently false.
The problem arises when one statistic is emphasized while the other is omitted, potentially leaving patients with an exaggerated impression of their personal benefit.
Statins have demonstrated cardiovascular benefits, especially among individuals at elevated risk. However, those benefits should be communicated in absolute as well as relative terms, alongside potential adverse effects and alternative or complementary preventive strategies.
The goal should never be to convince every patient to take a statin—or to convince every patient to avoid one. The goal should be to ensure that every patient understands the evidence well enough to make an informed decision.
When it comes to protecting your heart, knowing your cholesterol number is useful. Understanding your actual cardiovascular risk is even more important.
References
-
- Cholesterol Treatment Trialists’ (CTT) Collaboration. (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. The Lancet, 380(9841), 581–590. https://doi.org/10.1016/S0140-6736(12)60367-5
- Cholesterol Treatment Trialists’ Collaboration. (2022). Effect of statin therapy on muscle symptoms: An individual participant data meta-analysis of large-scale, randomised, double-blind trials. The Lancet, 400(10355), 832–845. https://doi.org/10.1016/S0140-6736(22)01545-8
- Covey, J. (2007). A meta-analysis of the effects of presenting treatment benefits in different formats. Medical Decision Making, 27(5), 638–654. https://doi.org/10.1177/0272989X07306783
- Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., & Saseen, J. J. (2019). 2018 AHA/ACC/multisociety guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139(25), e1082–e1143. https://doi.org/10.1161/CIR.0000000000000625
- Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J. M., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., Macfarlane, P. W., Packard, C. J., Stott, D. J., Westendorp, R. G., Shepherd, J., Davis, B. R., Pressel, S. L., Marchioli, R., Marfisi, R. M., … Ford, I. (2010). Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. The Lancet, 375(9716), 735–742. https://doi.org/10.1016/S0140-6736(09)61965-6
- Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., Mehlsen, J., Nieminen, M., O’Brien, E., & Östergren, J. (2003). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. The Lancet, 361(9364), 1149–1158. https://doi.org/10.1016/S0140-6736(03)12948-0
_______________
Robert Ferguson is a California- and Florida-based single father of two daughters, nutritionist, researcher, best-selling author, speaker, podcast and television host, health advisor, NAACP Image Award Nominee, creator of the Diet Free Life methodology, Chief Nutrition Officer for iCoura Health, and he serves on the Presidential Task Force on Obesity for the National Medical Association. You can e-mail Robert at robert@dietfreelife.com.
Watch a free online presentation on the BalanceOil+ and the BalanceTEST: WATCH NOW.
To order the BalanceOil+ with the BalanceTEST, > CLICK HERE.


“Great article! Your explanation of absolute vs. relative risk in the context of statins is incredibly clear and informative. Excellent job breaking down concepts, making them accessible for patients. This article is a valuable resource for anyone looking to make informed decisions about their health. Thank you for sharing such insights and for your dedication to keeping people informed!”